EarlySense wins FDA approval for heart, lung monitor

The company plans to initiate sales next year.

Israeli start-up EarlySense Ltd. has obtained US Food and Drug Administration (FDA) approval its ES-16 monitoring system for heart and respiratory rates in children and adults. The product has been named EverOn and the company plans to initiate sales next year.

The system uses a proprietary contact-free sensor, which minimizes patient discomfort and facilitates monitoring of patients both at home or at hospitals, clinics, and long-term care facilities. EarlySense is conducting trials of the system on patients suffering from chronic diseases, such as Asthma, COPD and CHF, as well as on critical care patients and patients hospitalized for various medical and post-operative conditions.

EarlySense CEO Mr. Avner Halperin and Dr. Danny Lange founded the company in 2004. Shareholders include ProSeed Venture Capital Fund (TASE:PRSD) with a 4.7% stake, Challenge Fund - Etgar, GlenRock Israel, Docor, Orange Blossom Ventures, and Bridge Investment Fund. According to IVC Online, the company has raised $6.2 million to date.

Published by Globes [online], Israel business news - www.globes-online.com - on November 20, 2007

© Copyright of Globes Publisher Itonut (1983) Ltd. 2007

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018